Evidence for non-covalent clusters of the c-met proto-oncogene product - PubMed (original) (raw)

Affiliations

PMID: 1317541

Evidence for non-covalent clusters of the c-met proto-oncogene product

D L Faletto et al. Oncogene. 1992 Jun.

Abstract

The met proto-oncogene is a member of the tyrosine kinase growth factor receptor family and is the receptor for hepatocyte growth factor (HGF) or scatter factor. The primary met product is a 150 kDa precursor that is glycosylated to generate a 170 kDa (p170met) proreceptor protein. The mature form of the receptor is generated by cleavage of p170met to yield a disulfide-linked 140 kDa beta-subunit (p140met) and a 45 kDa alpha-subunit (p45met). Both products are glycosylated. Under non-reducing conditions both p170met and the alpha, beta-disulfide-linked protein are detected as a 185 kDa product (p185met), but only alpha-beta heterodimeric p185met is cross-linked and rendered resistant to disulfide reduction with membrane-impermeable 6.4 A linker length cross-linking reagents. These data indicate that the p170 precursor is not on the cell surface. Cross-linking experiments using 12-A linker reagents yield multimeric forms of alpha-beta heterodimeric p185met greater than 500 kDa in size. These multimeric forms are produced in all cell lines tested regardless of the levels of protein expressed. These data suggest that alpha-beta heterodimeric p185met occurs in clusters or patches on the cell surface. Immunohistochemical analysis of met protein in the absence of ligand reveals a clustered staining pattern on the cell surface.

PubMed Disclaimer

Cited by

Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R. Maulik G, et al. J Cell Mol Med. 2002 Oct-Dec;6(4):539-53. doi: 10.1111/j.1582-4934.2002.tb00453.x. J Cell Mol Med. 2002. PMID: 12611639 Free PMC article.
In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.
Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I. Moshitch-Moshkovitz S, et al. Neoplasia. 2006 May;8(5):353-63. doi: 10.1593/neo.05634. Neoplasia. 2006. PMID: 16790084 Free PMC article.
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.
Lietha D, Chirgadze DY, Mulloy B, Blundell TL, Gherardi E. Lietha D, et al. EMBO J. 2001 Oct 15;20(20):5543-55. doi: 10.1093/emboj/20.20.5543. EMBO J. 2001. PMID: 11597998 Free PMC article.
Molecular mechanism of stomach carcinogenesis.
Tahara E. Tahara E. J Cancer Res Clin Oncol. 1993;119(5):265-72. doi: 10.1007/BF01212724. J Cancer Res Clin Oncol. 1993. PMID: 8440743
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.
Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Vande Woude G, Xu HE. Tolbert WD, et al. Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7. doi: 10.1073/pnas.0704290104. Epub 2007 Sep 5. Proc Natl Acad Sci U S A. 2007. PMID: 17804794 Free PMC article.

Evidence for non-covalent clusters of the c-met proto-oncogene product - PubMed (original) (raw)